2. Search Result
Search Result
Results for "

type+1+diabetes

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

11

Peptides

7

Inhibitory Antibodies

4

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-142295
    GNF2133
    1 Publications Verification

    		 DYRK Metabolic Disease
    GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes [1].
    GNF2133
  • HY-P99222
    Teplizumab

    MGA-031; PRV-031

    		 CD3 Metabolic Disease
    Teplizumab (MGA-031) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes [1] .
    Teplizumab
  • HY-P3507
    Dalazatide

    ShK-186

    		 Potassium Channel Metabolic Disease Inflammation/Immunology
    Dalazatide (ShK-186) is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease [1] .
    Dalazatide
  • HY-P1856
    Proinsulin C-peptide (human)
    1 Publications Verification

    		 Insulin Receptor PDGFR MAPKAPK2 (MK2) Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Proinsulin C-peptide (human) is a peptide consisting of 31 amino acids that links the A and B chains of proinsulin to ensure its correct folding. Proinsulin C-peptide (human) inhibits the high glucose-induced increase in PDGF-β receptor protein expression and the phosphorylation of p42/p44 MAP kinase. Proinsulin C-peptide (human) increases the deformability of erythrocytes derived from type 1 diabetes, inhibits insulin-induced neointimal thickening, and suppresses the proliferation of rat aortic smooth muscle cells cultured under high-glucose conditions [1] .
    Proinsulin C-peptide (human)
  • HY-109555
    Insulin glulisine

    HMR 1964

    		 Insulin Receptor Metabolic Disease Inflammation/Immunology
    Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes [1].
    Insulin glulisine
  • HY-142295A
    GNF2133 hydrochloride
    1 Publications Verification

    		 DYRK Metabolic Disease
    GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes [1].
    GNF2133 hydrochloride
  • HY-P1745
    InsB (9-23)

    Insulin B chain (9-23)

    		 MHC Insulin Receptor IFNAR Inflammation/Immunology
    InsB (9-23) (Insulin B chain (9-23)) is an HLA-DQ8-restricted insulin B-chain peptide composed of amino acid residues 9-23. InsB (9-23) serves as a major MHC II class-restricted antigen. InsB (9-23) supports the recognition and activation of T cells, stimulates the secretion of IFN-γ and cytokines, and induces cross-reactive immune responses. InsB (9-23)-specific CD4 T cells can initiate diabetes . InsB (9-23) can be used in research related to type 1 diabetes and autoimmune diabetes [1] .
    InsB (9-23)
  • HY-109854A
    (R)-Lisofylline

    (R)-Lisophylline

    		 STAT Metabolic Disease Inflammation/Immunology
    (R)-Lisofylline ((R)-Lisophylline) is a (R)-enantiomer of the metabolite of Pentoxifylline with anti-inflammatory properties. (R)-Lisofylline is a lysophosphatidic acid acyltransferase inhibitor with an IC50 of 0.6 μM and interrupts IL-12 signaling-mediated STAT4 activation. (R)-Lisofylline has the potential for type 1 diabetes, autoimmune disorders research [1] .
    (R)-Lisofylline
  • HY-P99383
    Volagidemab

    REMD-477; AMG-477

    		 GCGR Metabolic Disease
    Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D) [1] .
    Volagidemab
  • HY-W142432
    Perfluoroundecanoic acid

    		Biochemical Assay Reagents β-catenin Wnt Arginase TGF-beta/Smad mTOR Akt ERK Atg8/LC3 p62 Autophagy Metabolic Disease Inflammation/Immunology Cancer
    Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation [1] .
    Perfluoroundecanoic acid
  • HY-P3507A
    Dalazatide TFA

    ShK-186 TFA

    		 Potassium Channel Metabolic Disease Inflammation/Immunology
    Dalazatide (ShK-186) TFA is a specific Kv1.3 potassium channel peptide inhibitor. Dalazatide TFA can be used in the study of autoimmune diseases such as multiple sclerosis (MS), lupus erythematosus, psoriasis, rheumatoid arthritis, type 1 diabetes and inflammatory bowel disease [1] .
    Dalazatide TFA
  • HY-135783
    AT 1001
    1 Publications Verification

    		 nAChR Neurological Disease Metabolic Disease Inflammation/Immunology
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease [1] .
    AT 1001
  • HY-119684
    Maresin 2

    		NOD-like Receptor (NLR) Interleukin Related Neurological Disease Inflammation/Immunology
    Maresin 2 is an anti-inflammatory and pro-resolving mediator. Maresin 2 drives intestinal epithelial cell migration by activating the focal cell-matrix adhesion signaling pathway in primary human intestinal epithelial cells, thereby promoting mucosal wound repair. Maresin 2 alleviates nociceptive and anxiety-like behaviors in rats with type 1 diabetes by inhibiting IL-1β in the spinal cord and prefrontal cortex. Maresin 2 attenuates allergic airway inflammation in mice by inhibiting the activation of the NLRP3 inflammasome, Th2-type immune responses, and oxidative stress. Maresin 2 inhibits inflammatory and neuropathic trigeminal neuralgia and reduces neuronal activation in the trigeminal ganglion. Maresin 2 promotes inflammation resolution and mucosal repair after DSS-induced colitis or biopsy-induced colonic mucosal injury [1] .
    Maresin 2
  • HY-P99211
    Otelixizumab

    ChAglyCD3; TRX 4

    		 CD3 Metabolic Disease
    Otelixizumab (ChAglyCD3) is an anti-human CD3 monoclonal antibody and can be used for the research of type 1 diabetes [1].
    Otelixizumab
  • HY-113266
    Valerylcarnitine
    2 Publications Verification

    		 Endogenous Metabolite Metabolic Disease
    Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes [1] .
    Valerylcarnitine
  • HY-138688
    Cinnamyl-3,4-dihydroxy-α-cyanocinnamate

    CDC

    		 Lipoxygenase Metabolic Disease Cancer
    Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent 12/15-Lipoxygenases (LO) inhibitor. Cinnamyl-3,4-dihydroxy-α-cyanocinnamate has the potential for the research of type 1 diabetes mellitus [1].
    Cinnamyl-3,4-dihydroxy-α-cyanocinnamate
  • HY-113033
    Pentosidine

    		Others Biochemical Assay Reagents Neurological Disease Metabolic Disease Inflammation/Immunology
    Pentosidine is a fluorescent advanced glycation end product (AGE) and cross-linker. Pentosidine is a fluorescent cross-linked structure formed by lysine and arginine in sugar oxidation reactions, and it is commonly found in collagen, skin, bone, lens and plasma proteins . Pentosidine is used in research related to type 1 diabetes, brown cataracts, rheumatoid arthritis, atherosclerosis and neurodegenerative diseases [1] .
    Pentosidine
  • HY-164595
    IHMT-MST1-39

    		Hippo (MST) Apoptosis AMPK Metabolic Disease
    IHMT-MST1-39 is an orally active inhibitor for MST kinase, with IC50 of 42, 109, 286, 159 nM for MST1, MST2, MST3, MST4. IHMT-MST1-39 activates the AMPK signaling pathway in liver cells, reduces apoptosis of pancreatic β-cells. IHMT-MST1-39 can be used for the studies of type 1 diabetes (T1D) and type 2 diabetes (T2D) [1].
    IHMT-MST1-39
  • HY-P990001
    Anti-Mouse IL-10 Antibody (JES5-2A5)
    1 Publications Verification

    		 Interleukin Related Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Anti-Mouse IL-10 Antibody (JES5-2A5) is an anti-mouse IL-10 IgG1 monoclonal antibody. Anti-Mouse IL-10 Antibody (JES5-2A5) restores the anti-tumor activity of IL-6 by blocking the IL-10/SOCS3 axis. Anti-Mouse IL-10 Antibody (JES5-2A5) can reverse microcirculation and cognitive deficits. Anti-Mouse IL-10 Antibody (JES5-2A5) can be used for researches on cancer and metabolic disease such as osteosarcoma and type 1 diabetes mellitus (T1DM) [1] .
    Anti-Mouse IL-10 Antibody (JES5-2A5)
  • HY-126042
    (±)-Lisofylline

    (±)-Lisophylline

    		 Interleukin Related Metabolic Disease Inflammation/Immunology
    (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research [1].
    (±)-Lisofylline
  • HY-P5396A
    GAD65 (524-543) acetate

    		Amino Acid Decarboxylase Others
    GAD65 (524-543) acetate is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) acetate is one of the first fragments of the islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) acetate is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) acetate increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells [1].
    GAD65 (524-543) acetate
  • HY-P991326
    BL-9020

    EDP-10; JHL-1311

    		 Interleukin Related Endocrinology
    BL-9020 is a human monoclonal antibody (mAb) targeting NKp46/NCR1. BL-9020 can be used in type 1 diabetes mellitus research.
    BL-9020
  • HY-10397
    EP1013

    F1013

    		 Caspase Metabolic Disease
    EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes [1].
    EP1013
  • HY-P991552
    AFM15

    		CD3 Metabolic Disease Inflammation/Immunology
    AFM15 is a humanized monoclonal antibody inhibitor targeting CD3E. AFM15 can be used to study metabolic and immune system diseases, such as type 1 diabetes and inflammatory bowel disease (IBD) [1].
    AFM15
  • HY-124665
    LMP-420

    		TNF Receptor Interleukin Related Infection Metabolic Disease Inflammation/Immunology
    LMP-420 is a selective tumor necrosis factor-α (TNF-α) inhibitor. LMP-420 reduces the release of pro-inflammatory cytokines (e.g., IL-1β, IL-2), inducing the expression of anti-inflammatory cytokine IL-10 and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines (e.g., IP-10, MCP-1) to reduce immune cell infiltration. LMP-420 is promising for research of type 1 diabetes mellitus, inflammatory diseases (e.g., colitis), and HIV-Mycobacterium tuberculosis coinfection [1].
    LMP-420
  • HY-158525
    A3G3S3 glycan

    A3G3S3 N-linked oligosaccharide

    		 Biochemical Assay Reagents Others
    A3G3S3 glycan (A3G3S3 N-linked oligosaccharide) is an N-glycosylated plasma protein that plays an important role in indicating different stages of type 1 diabetes [1].
    A3G3S3 glycan
  • HY-P10612
    Tetanus toxin peptide

    		Bacterial Metabolic Disease
    Tetanus toxin peptide is a specific peptide isolated from the toxin produced by Clostridium tetani. Tetanus toxin peptide can be used as an immunogen to induce diabetes in mice. Tetanus toxin peptide can be used in the study of type 1 diabetes [1].
    Tetanus toxin peptide
  • HY-113266R
    Valerylcarnitine (Standard)

    		Reference Standards Endogenous Metabolite Metabolic Disease
    Valerylcarnitine (Standard) is the analytical standard of Valerylcarnitine. Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes [1] .
    Valerylcarnitine (Standard)
  • HY-126042R
    (±)-Lisofylline (Standard)

    (±)-Lisophylline (Standard)

    		 Interleukin Related Reference Standards Metabolic Disease Inflammation/Immunology
    (±)-Lisofylline (Standard) is the analytical standard of (±)-Lisofylline. This product is intended for research and analytical applications. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research [1].
    (±)-Lisofylline (Standard)
  • HY-113266S
    Valerylcarnitine-d9

    C5:0 L-carnitine-d9

    		 Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    Valerylcarnitine-d9 (C5:0 L-carnitine-d9) is the deuterium labeled Valerylcarnitine (HY-113266). Valerylcarnitine is an endogenous metabolite, belonging to the short-chain acylcarnitines. Valerylcarnitine acts as a metabolomic biomarker for ionizing radiation exposure in nonhuman primates. Valerylcarnitine can be used for the research of type 1 diabetes [1] .
    Valerylcarnitine-d9
  • HY-126042S4
    (±)-Lisofylline-d4

    (±)-Lisophylline-d4

    		 Isotope-Labeled Compounds Interleukin Related Metabolic Disease Inflammation/Immunology
    (±)-Lisofylline-d4 ((±)-Lisophylline-d4) is deuterium labeled (±)-Lisofylline. (±)-Lisofylline ((±)-Lisophylline) is the racemate of Lisofylline. Lisofylline inhibits the generation of phosphatidic acid and free fatty acids. Lisofylline also blocks the release of pro-inflammatory cytokines in oxidative tissue injury, in response to cancer chemotherapy and in experimental sepsis. Lisofylline can be used for Type 1 diabetes research [1].
    (±)-Lisofylline-d4
  • HY-176865
    Anti-inflammatory agent 106

    		Drug Derivative Inflammation/Immunology
    Anti-inflammatory agent 106 (Example 2) is a derivative of Paeonol (HY-N0159). Anti-inflammatory agent 106 has potent anti-inflammatory activity. Anti-inflammatory agent 106 effectively inhibits xylene-induced ear swelling in mouse models. Anti-inflammatory agent 106 can be used for inflammatory diseases like rheumatoid arthritis, psoriasis and type 1 diabetes research [1].
    Anti-inflammatory agent 106
  • HY-125316
    AMG-151

    ARRY-403

    		 Endogenous Metabolite Metabolic Disease
    AMG-151 (ARRY-403) is a glucokinase agonist with fasting plasma glucose (FPG) lowering activity. AMG-151 showed a significant linear dose-response trend compared with placebo in a randomized, placebo-controlled Phase IIa study. The use of AMG-151 was associated with a higher incidence of hypoglycemia and hypertriglyceridemia. AMG-151 may serve as a potential compound for the inhibition of type 1 diabetes [1].
    AMG-151
  • HY-138990
    GK563

    		Phospholipase Apoptosis Inflammation/Immunology
    GK563 is a selective Ca 2+-independent phospholipase A2 (GVIA iPLA2) inhibitor with an IC50 value of 1 nM. GK563 is 22000 times more active against GVIA iPLA2 than GIVA cPLA2. GK563 reduces β-cell apoptosis induced by proinflammatory cytokines, raising the possibility that it can be beneficial in countering autoimmune diseases, such as type 1 diabetes [1].
    GK563
  • HY-145492
    Δ7(Z)-C14-HSL

    N-(3-Oxo-7Z-tetradecenoyl)-L-homoserine lactone

    		 Drug Derivative Inflammation/Immunology
    Δ7(Z)-C14-HSL (Compound 12) is an immunosuppressive agent that can inhibit the proliferation of mouse splenic cells with an IC50 of 17 μM. Δ7(Z)-C14-HSL can be used for further studying its potential as a molecular mechanism in TNF-R-driven immune diseases, especially autoimmune diseases such as psoriasis, rheumatoid arthritis, and type 1 diabetes [1].
    Δ7(Z)-C14-HSL
  • HY-N11723
    Catenarin

    Katenarin

    		 CCR CXCR p38 MAPK JNK Calcium Channel Infection Metabolic Disease Inflammation/Immunology
    Catenarin, an anthraquinone compound, inhibits CCR5- and CXCR4-mediated chemotaxis. Catenarin reduces the phosphorylation of mitogen-activated protein kinases (p38 and JNK) and their upstream kinases (MKK6 and MKK7), and calcium mobilization. Catenarin shows anti-inflammatory effect and suppresses leukocyte migration in the diabetes. Catenarin exhibits significant inhibitory effects against Gram-positive bacteria. Catenarin prevents type 1 diabetes (T1D) in nonobese diabetic mice [1][2].
    Catenarin
  • HY-P5396
    GAD65 (524-543)

    		Amino Acid Decarboxylase Others
    GAD65 (524-543) is a biological active peptide with amino acids 524 to 543 fragment of glutamic acid decarboxylase 65 (GAD65). GAD65 (524-543) is one of the first fragments of islet antigen to induce proliferative T cell responses in the non-obese diabetic (NOD) mouse model of spontaneous autoimmune diabetes. GAD65 (524-543) is a specific, possibly low affinity, stimulus for the spontaneously arising diabetogenic T cell clone BDC2.5. Immunization with GAD65 (524-543) increases the susceptibility of the NOD mice to type 1 diabetes induced by the adoptive transfer of BDC2.5 T cells [1].
    GAD65 (524-543)
  • HY-W142432S
    Perfluoroundecanoic acid-13C7

    		Isotope-Labeled Compounds Biochemical Assay Reagents β-catenin Wnt Arginase TGF-beta/Smad mTOR Akt ERK Atg8/LC3 p62 Autophagy Metabolic Disease
    Perfluoroundecanoic acid- 13C7 is the 13C-labeled Perfluoroundecanoic acid (HY-W142432). Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation [1] .
    Perfluoroundecanoic acid-13C7
  • HY-119119
    ATV399

    		NO Synthase Apoptosis Metabolic Disease Inflammation/Immunology
    ATV399 is an inducible nitric oxide synthase (iNOS) inhibitor. ATV399 reduces NO production via allosteric inhibition of iNOS dimerization, thereby protecting rat pancreatic islet β-cells from cytokine-induced mitochondrial stress, endoplasmic reticulum stress, and apoptosis. ATV399 can be used in research related to type 1 diabetes [1].
    ATV399
  • HY-183955
    GNF7156

    		DYRK GSK-3 Metabolic Disease Inflammation/Immunology
    GNF7156 is a DYRK1A/GSK3B inhibitor, IC50 values of 100 nM for DYRK1A and 40 nM for GSK3B. GNF7156 inhibits DYRK1A and GSK3B kinase activity and induces NFAT nuclear retention. GNF7156 stimulates beta-cell cycle entry and division and maintains insulin secretory capacity. GNF7156 can be used for the research of type 1 diabetes, and type 2 diabetes [1] .
    GNF7156
  • HY-D3174
    PiF

    		Fluorescent Dye Metabolic Disease Inflammation/Immunology
    PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive 18F to prepare a PET tracer. PiF can be used for research on type 1 diabetes [1].
    PiF
  • HY-181335
    SKL1223

    		Arrestin Metabolic Disease Inflammation/Immunology
    SKL1223 is an orally effective thioredoxin-interacting protein (TXNIP) inhibitor with an IC50 of 0.64 µM. SKL1223 interacts with the E-box region of the TXNIP promoter to inhibit TXNIP transcription and related signaling pathways. SKL1223 reduces hepatic glucose output. SKL1223 exerts hypoglycemic effects by regulating the action of glucagon, and modulates blood glucose levels in Streptozotocin (HY-13753)-induced and obesity-induced diabetic mice. SKL1223 can be used in the research of type 1 diabetes and type 2 diabetes [1].
    SKL1223
  • HY-W750419
    cis-9-Hexadecenoylcarnitine inner salt

    Palmitoleoylcarnitine (C16:1)

    		 Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    cis-9-Hexadecenoylcarnitine inner salt (Palmitoleoylcarnitine (C16:1)) is a long-chain acylcarnitine controlling fatty acid metabolism and mitochondrial function. cis-9-Hexadecenoylcarnitine inner salt accumulates in colorectal cancer cells. cis-9-Hexadecenoylcarnitine inner salt exists in plants and mediates lipid anabolic development. cis-9-Hexadecenoylcarnitine inner salt acts as a metabolic marker for type 1 diabetes and inflammatory bowel disease plasma. cis-9-Hexadecenoylcarnitine inner salt can be used for research on diabetes, metabolism, and inflammatory bowel disease [1] .
    cis-9-Hexadecenoylcarnitine inner salt
  • HY-P992159
    Anti-ZnT8 Antibody (mAb43)

    		SLC39 (Zinc Transporter) Metabolic Disease Inflammation/Immunology
    Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes [1].
    Anti-ZnT8 Antibody (mAb43)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: